We will be performing maintenance on this site on March 24, 2024 starting at 6:00 am until 8:00 am.  We apologize for the inconvenience.  

Mobile App

Google Play Apple Store


Pulmonary Arterial Hypertension: The Diagnosis You Don't Want to Miss - Updated 6/27/2023
AMA/ANCC/ACPE Activity - Video Lecture Library
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This on-demand presentation is designed using a case-based discussion on tools to improve the diagnosis of PAH and the importance of early referral.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Jean Elwing, MD Jean Elwing, MD
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Cincinnati


Supported by independent educational grants from

United Therapeutics, a public benefit company; Bayer U.S.;

and Actelion Pharmaceuticals U.S., Inc.,

A Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: April 18, 2023

Release Date: January 19, 2023

Expiration Date: March 31, 2024

March 31, 2024
Mini Module